TherapeuticsMD (TXMD) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS

TherapeuticsMD (NASDAQ:TXMD) posted its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.06, Fidelity Earnings reports. TherapeuticsMD had a negative net margin of 582.86% and a negative return on equity of 80.75%. The company had revenue of $3.47 million for the quarter, compared to analyst estimates of $4.43 million. During the same quarter in the previous year, the firm posted ($0.07) earnings per share. The company’s quarterly revenue was down 21.5% compared to the same quarter last year.

Shares of NASDAQ:TXMD traded up $0.30 during trading on Thursday, reaching $4.97. The company had a trading volume of 3,789,520 shares, compared to its average volume of 2,607,102. The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of -13.43 and a beta of 1.40. TherapeuticsMD has a 12 month low of $4.30 and a 12 month high of $7.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 7.88 and a quick ratio of 7.79.

A number of research firms recently weighed in on TXMD. ValuEngine raised shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a report on Friday, September 21st. Oppenheimer set a $14.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday, September 26th. Cantor Fitzgerald set a $27.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Thursday, September 27th. BidaskClub raised shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 29th. Finally, Zacks Investment Research raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Saturday, August 25th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. TherapeuticsMD presently has a consensus rating of “Buy” and an average target price of $13.45.

In other news, insider John C.K. Iv Milligan sold 250,000 shares of the stock in a transaction on Wednesday, October 24th. The shares were sold at an average price of $5.35, for a total value of $1,337,500.00. Following the transaction, the insider now owns 1,597,419 shares of the company’s stock, valued at approximately $8,546,191.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Robert G. Finizio sold 184,000 shares of the stock in a transaction on Friday, September 7th. The stock was sold at an average price of $6.24, for a total transaction of $1,148,160.00. Following the completion of the transaction, the chief executive officer now directly owns 18,485,559 shares in the company, valued at approximately $115,349,888.16. The disclosure for this sale can be found here. Insiders sold a total of 2,158,800 shares of company stock worth $12,946,562 in the last three months. Insiders own 22.85% of the company’s stock.

Several large investors have recently modified their holdings of the company. BlackRock Inc. increased its holdings in shares of TherapeuticsMD by 4.4% in the 2nd quarter. BlackRock Inc. now owns 14,533,524 shares of the company’s stock worth $90,690,000 after buying an additional 608,470 shares during the last quarter. Voya Investment Management LLC increased its holdings in shares of TherapeuticsMD by 7.7% in the 2nd quarter. Voya Investment Management LLC now owns 3,419,174 shares of the company’s stock worth $21,336,000 after buying an additional 242,995 shares during the last quarter. Northern Trust Corp increased its holdings in shares of TherapeuticsMD by 4.0% in the 2nd quarter. Northern Trust Corp now owns 2,086,552 shares of the company’s stock worth $13,021,000 after buying an additional 81,062 shares during the last quarter. OppenheimerFunds Inc. increased its holdings in shares of TherapeuticsMD by 17.4% in the 2nd quarter. OppenheimerFunds Inc. now owns 1,932,439 shares of the company’s stock worth $12,058,000 after buying an additional 286,123 shares during the last quarter. Finally, AXA increased its holdings in shares of TherapeuticsMD by 37.8% in the 3rd quarter. AXA now owns 1,463,274 shares of the company’s stock worth $9,599,000 after buying an additional 401,228 shares during the last quarter. 66.20% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by WKRB News and is the property of of WKRB News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.wkrb13.com/2018/11/08/therapeuticsmd-txmd-releases-quarterly-earnings-results-beats-expectations-by-0-06-eps.html.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Featured Article: Are analyst ratings accurate?

Earnings History for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply